Hyponatremia after pediatric surgery: Randomized trial of fluid composition on antidiuretic hormone response

What Was Tested

Researchers studied Vasopressin in this randomized controlled trial publication.

The researchers examined the underlying mechanisms of whether hyponatremia could be induced by hypotonic solution administration after the postoperative invasive phase (POIP).

01/11/2017 IMPACT: After the postoperative invasive phase, non-osmotic antidiuretic hormone (ADH) secretion due to surgical stress persisted, resulting in an excess ADH state for at least 3 postoperative days (PODs).

Who Took Part

According to the abstract, 100 patients were involved.

PubMed indexes the participants as infants, young children, children and teenagers, both men and women.

The researchers included patients who had undergone surgery with expected oral feeding resumption after postoperative day (POD) 3.

In this open-label, randomized controlled trial, 100 patients were assigned to three groups by sodium concentrations ([Na]) used for maintenance infusions: 136 mEq/L (ISO) (n = 34), 68 mEq/L (HYPO) (n = 33), and 34 mEq/L (exHYPO) (n = 33).

How the Study Was Run

The design is described as randomized and open-label.

The patients were allocated by chance, so the Vasopressin group and the comparison group should start out alike.

Nothing was hidden in this open-label Vasopressin study: the patients and staff both knew the treatment.

Ringer's solution was used in all groups for the first 12 h postoperatively, then switched to a maintenance solution.

Blood samples were drawn and evaluated on POD 3.

What Was Measured

Topics PubMed links to this paper include Hyponatremia, Vasopressins, Sodium, Hypotonic Solutions, Potassium, Postoperative Complications and Ringer's Solution.

What This Means in Plain Language

The paper is a randomized and open-label study of Vasopressin in 100 patients.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (Pediatric research), a journal based in United States.

More context: the Vasopressin compound page, all human trials.